Indivior PLC (NASDAQ:INDV) Short Interest Down 15.7% in September

Indivior PLC (NASDAQ:INDV) was the target of a large decrease in short interest in the month of September. As of September 30th, there was short interest totalling 800,900 shares, a decrease of 15.7% from the September 15th total of 950,000 shares. Approximately 0.6% of the shares of the stock are short sold. Based on an average trading volume of 859,800 shares, the short-interest ratio is presently 0.9 days.

Indivior Price Performance

Indivior stock traded up $0.14 during mid-day trading on Wednesday, hitting $8.14. 875,271 shares of the company were exchanged, compared to its average volume of 433,151. Indivior has a 12-month low of $7.33 and a 12-month high of $23.22. The company has a market capitalization of $1.12 billion, a P/E ratio of 804.00 and a beta of 0.68. The business’s 50 day simple moving average is $10.77 and its two-hundred day simple moving average is $14.43. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.85 and a quick ratio of 0.68.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.40 by $0.04. The firm had revenue of $299.00 million during the quarter, compared to analysts’ expectations of $285.90 million. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. Analysts forecast that Indivior will post 1.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Indivior

A number of institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp purchased a new stake in Indivior in the 2nd quarter worth approximately $188,000. VELA Investment Management LLC purchased a new stake in Indivior in the 2nd quarter valued at about $235,000. XTX Topco Ltd purchased a new position in shares of Indivior during the 2nd quarter worth about $249,000. Cubist Systematic Strategies LLC grew its holdings in Indivior by 32.0% in the second quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock valued at $407,000 after purchasing an additional 6,121 shares during the period. Finally, Cannon Global Investment Management LLC acquired a new position in Indivior during the first quarter worth approximately $563,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Wall Street Analysts Forecast Growth

INDV has been the topic of several recent research reports. Piper Sandler reiterated an “overweight” rating and issued a $15.00 price objective (down from $22.00) on shares of Indivior in a research report on Friday, October 11th. Craig Hallum reduced their price target on shares of Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, October 11th.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.